Entering text into the input field will update the search result below

Cotinga Pharma's lead drug shows encouraging action in early-stage study

  • Preliminary data from a Phase 1b/2a clinical trial evaluating Cotinga Pharmaceuticals' (OTCPK:COTQF +1.6%) lead candidate COTI-2, combined with the chemo agent cisplatin, in patients with p53-mutated solid tumors showed a favorable safety profile while two subjects experienced either stable cancer or regression.
  • No dose-limiting toxicities have been observed to date.
  • The company says COTI-2 restores the function of mutant p53, a tumor suppressor gene, inducing cancer cell death irrespective of the type of cancer. It has Orphan Drug status in the U.S. for ovarian cancer.
  • Development is ongoing.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
COTQF
--
COT.H:CA
--